Protein Tyrosine Phosphatase

Cat. No.

A34656

CAS No.

2169223-49-6

JAB-3068 hydrochloride

Synonyms: SHP2-IN-6 hydrochloride

JAB-3068 hydrochloride is a potent inhibitor of SHP2, exhibiting an IC50 value of 25.8 nM. This compound is relevant for research applications investigating the modulation of SHP2 activity, which is implicated in various signaling pathways associated with cancer and immunology. Its inhibition of SHP2 may provide insights into therapeutic strategies targeting related diseases.

Cat. No.

A34657

CAS No.

2987135-92-0

SHP2-IN-9

SHP2-IN-9 is a selective inhibitor of SHP2, with an IC50 value of 1.174 μM and enhanced penetration across the blood-brain barrier. It displays an 85-fold preference for SHP2 over SHP1, effectively inhibiting SHP2-mediated cell signaling pathways and cancer cell proliferation. Research applications include the study of cervix cancer and glioblastoma growth in vivo, making it a valuable tool for investigating targeted cancer therapies.

Cat. No.

A34658

CAS No.

2951854-02-5

SHP2-IN-13

SHP2-IN-13 is a selective allosteric inhibitor targeting the SHP2 enzyme, specifically at the "tunnel site," with an IC50 value of 83.0 nM. This compound demonstrates significant potential for therapeutic applications in cancers associated with receptor tyrosine kinase (RTK) oncogenic drivers and in the study of diseases related to SHP2 dysregulation. Its oral bioavailability enhances its utility for in vivo research settings.

Cat. No.

A34659

CAS No.

1957276-35-5

SHP836

SHP836 is an allosteric inhibitor of the SHP2 protein, demonstrating an IC50 value of 12 μM for the full-length enzyme. This compound serves as a crucial tool for studying the role of SHP2 in various cellular processes, including signal transduction and oncogenesis. SHP836 is particularly relevant in the context of cancer research, where modulation of SHP2 activity may impact tumor growth and response to therapies.

Cat. No.

A34661

CAS No.

2411321-29-2

IACS-15414

IACS-15414 is a potent inhibitor of SHP2, exhibiting an IC50 value of 122 nM. This compound demonstrates significant biological activity by modulating signaling pathways associated with cancer cell proliferation and survival. It serves as a valuable tool for research focused on SHP2-related mechanisms in cancer therapy and other disease models.

Cat. No.

A34662

CAS No.

2235394-90-6

SHP389

SHP389 is an allosteric inhibitor of SHP2, demonstrating an IC50 of 36 nM for both SHP2 and phosphorylated ERK. This compound is valuable in research focused on the modulation of SHP2 activity and its role in signaling pathways, particularly those involved in oncogenesis. Its specificity and potency make it an essential tool for studies investigating SHP2-related mechanisms in disease.

Cat. No.

A34663

CAS No.

1177131-02-0

PHPS1 sodium

PHPS1 sodium is a potent and selective inhibitor of the protein tyrosine phosphatase Shp2, with a competitive inhibition constant (Ki) of 0.73 μM. It exhibits specificity over related phosphatases, including Shp1, PTP1B, and the mutant Shp2-R362K, with Ki values of 5.8 μM, 10.7 μM, and 5.8 μM, respectively. This compound is valuable for studies in cancer research, particularly those involving signaling pathways mediated by Shp2, and can be utilized in evaluating potential therapeutic interventions in diseases associated with aberrant Shp2 activity.

Cat. No.

A34665

CAS No.

2907659-86-1

BPDA2

BPDA2 is a selective and competitive inhibitor of SHP2, demonstrating an IC50 of 92.0 nM for SHP2 while showing significantly higher IC50 values for SHP1 and SHP1B at 33.39 µM and 40.71 µM, respectively. This compound effectively downregulates mitogenic and cell survival signaling pathways, as well as receptor tyrosine kinase expression. BPDA2 is valuable for research into the modulation of SHP2-mediated signaling in breast cancer cell phenotypes.

Cat. No.

A34666

CAS No.

1143579-78-5

II-B08

II-B08 is a reversible, noncompetitive inhibitor of SHP2, exhibiting an IC50 of 5.5 μM. This compound selectively inhibits SHP2 with reduced activity against SHP1 and PTP1B, demonstrating IC50 values of 15.7 μM and 14.3 μM, respectively. II-B08 is primarily utilized in cancer research to investigate the role of SHP2 signaling in tumorigenesis and therapeutic resistance.

Cat. No.

A34667

CAS No.

1710337-31-7

GS-493

GS-493 is a selective inhibitor of the protein tyrosine phosphatase SHP2 (PTPN11), demonstrating an IC50 of 71 nM. This compound exhibits significantly higher potency against SHP2 compared to its relatives, SHP1 and PTP1B, with 29-fold and 45-fold increased activity, respectively. GS-493 effectively inhibits cellular motility and proliferation of cancer cells, showcasing its potential for antitumor applications in cancer research.

Cat. No.

A34668

CAS No.

1801764-98-6

SHP2-IN-39

SHP2-IN-39 is a potent inhibitor of the protein tyrosine phosphatase SHP2, exhibiting an IC50 value of 0.007 μM. This compound is instrumental in cancer research, as it modulates downstream signaling pathways involved in tumorigenesis and cellular proliferation. Its high specificity and efficacy make it a valuable tool for investigating the role of SHP2 in various cancer models.

Cat. No.

A34669

CAS No.

2956716-97-3

YF704

YF704 is a selective allosteric inhibitor of SHP2, exhibiting an IC50 of 0.25 μM. This compound demonstrates significant antiproliferative effects and induces apoptosis in various cancer cell lines. Additionally, YF704 effectively downregulates Erk1/2 and Akt phosphorylation levels, highlighting its potential utility in cancer research and therapeutic applications targeting SHP2-mediated signaling pathways.

Cat. No.

A34670

CAS No.

2802453-88-7

SHP2-IN-22

SHP2-IN-22 is an allosteric inhibitor of SHP2, demonstrating an IC50 value of 17.7 nM. This compound effectively inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells, making it a valuable tool in cancer research. SHP2-IN-22 is particularly relevant for investigations involving KRAS mutant cancers, providing insights into targeted therapeutic strategies.

Cat. No.

A34671

CAS No.

2941498-94-6

SHP2-IN-20

SHP2-IN-20 is a selective inhibitor of the protein tyrosine phosphatase SHP2, displaying an IC50 value of 3 nM. This compound is primarily utilized in research focused on glioblastoma, where it aids in the investigation of SHP2's role in oncogenic signaling pathways and potential therapeutic interventions.

Cat. No.

A34672

CAS No.

2415989-91-0

SHP2-IN-23

SHP2-IN-23 is a potent inhibitor of the SHP2 protein, exhibiting an IC50 of 38 nM and demonstrating outstanding in vivo efficacy and pharmacokinetic properties. This compound effectively inhibits ERK phosphorylation with an IC50 of 5 nM, making it a valuable tool for research applications targeting cellular signaling pathways and cancer biology. Its oral bioavailability facilitates its use in preclinical studies to investigate the therapeutic potential of SHP2 modulation.

Cat. No.

A34673

CAS No.

3081261-84-6

SHP2-IN-41

SHP2-IN-41 is a potent inhibitor of the SHP2 protein, exhibiting an IC50 of less than 0.1 μM in biochemical assays. It also demonstrates significant inhibitory activity against KYSE-520 cancer cells with an IC50 of less than 0.1 μM. This compound serves as a valuable tool in cancer research, particularly in studies exploring SHP2's role in oncogenic signaling pathways.

Cat. No.

A34674

CAS No.

313952-63-5

DSHN

DSHN is a potent small heterodimer partner (SHP) activator that plays a critical role in regulating gene expression. It effectively inhibits Ccl2 expression and secretion through the inhibition of p65 activation of the Ccl2 promoter. DSHN is suitable for research applications in cancer studies, particularly in exploring the mechanisms of inflammation and tumor progression.

Cat. No.

A34675

CAS No.

2673400-91-2

SHP2-IN-14

SHP2-IN-14 is a potent allosteric inhibitor of SHP2, displaying an IC50 of 7 nM. This compound demonstrates significant anti-tumor activity, effectively inhibiting tumor progression in NCI-H358 tumor-bearing mice. Moreover, SHP2-IN-14 showcases favorable pharmacokinetic properties, contributing to its potential utility in cancer research and therapeutic applications.

Cat. No.

A34676

CAS No.

3043685-80-6

SHP2-IN-32

SHP2-IN-32 is an allosteric inhibitor of SHP2, exhibiting a potent inhibitory activity with an IC50 value of 0.13 nM. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. SHP2-IN-32 can be utilized in studies focusing on SHP2-mediated signaling pathways and therapeutic interventions for malignancies.

Cat. No.

A34679

CAS No.

2296718-09-5

SHP2 inhibitor LY6

Synonyms: LY6

SHP2 inhibitor LY6 is a selective inhibitor targeting the SHP2 protein tyrosine phosphatase, exhibiting an IC50 of 9.8 µM. This compound effectively disrupts SHP2-mediated signaling pathways and cell proliferation. It is suitable for research applications investigating SHP2's role in various cellular processes and its implications in cancer and other diseases.

Cat. No.

A34680

CAS No.

54755-93-0

SHP2-IN-5

SHP2-IN-5 is a potent inhibitor of SHP2, with an IC50 of 97 nM. SHP2 is a crucial non-receptor protein tyrosine phosphatase that plays a significant role in regulating cell growth and proliferation. This compound has demonstrated potential for application in cancer research and other SHP2-related human diseases, making it a valuable tool for investigating therapeutic strategies targeting SHP2 pathways.

Cat. No.

A34682

CAS No.

2818955-47-2

SHP2-IN-44

SHP2-IN-44 is an allosteric inhibitor of SHP2, exhibiting an IC50 of 27 nM. This compound effectively inhibits ERK phosphorylation with an IC50 of 299 nM while demonstrating a lack of off-target activity on hERG channels. SHP2-IN-44 displays broad-spectrum anticancer activity, making it a valuable tool for research into juvenile myelomonocytic leukemia, neuroblastoma, and breast cancer, as well as conditions like Noonan syndrome and LEOPARD syndrome.

Cat. No.

A34684

CAS No.

2941498-93-5

SHP2-IN-17

SHP2-IN-17 is a potent inhibitor of Src homology 2 domain-containing phosphatase 2 (SHP2) with an IC50 value of 2 nM. This compound demonstrates significant anti-tumor activity, making it suitable for research applications in glioblastoma. Its ability to modulate SHP2 activity can help elucidate the underlying mechanisms of tumor progression and therapeutic resistance.

Cat. No.

A34685

CAS No.

2941498-84-4

SHP2-IN-19

SHP2-IN-19 is a selective SHP2 inhibitor with an IC50 of 3 nM, demonstrating potent inhibitory activity against the SHP2 enzyme. This compound is primarily utilized in the study of glioblastoma, offering valuable insights into the role of SHP2 signaling in cancer progression and therapeutic resistance. Its high potency makes it a useful tool for evaluating SHP2's contribution to various biological processes and potential treatments in oncological research.

Cat. No.

A34686

CAS No.

2222280-82-0

SHP844

SHP844 is a selective SHP2 inhibitor, with an IC50 of 18.9 µM. SHP2 is a protein tyrosine phosphatase that plays a critical role in modulating tyrosine phosphorylation, influencing cellular processes such as proliferation, differentiation, and survival. This compound is valuable for research applications aimed at elucidating SHP2's role in various signaling pathways and its potential as a therapeutic target in cancer and other diseases.